EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antithrombotic Therapy in People with Hemophilia—A Narrative Review

Azusa Nagao iD, Shinichi Goto iD, Shinya Goto iD

Thrombosis and Haemostasis · 01.11.2025 · 125 (11) · 1060-1068

DOI: 10.1055/a-2548-4192 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.11.2025. Verfasst von Azusa Nagao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Thrombosis, Fibrinolytic Agents, Blood Coagulation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the life expectancy of individuals with hemophilia continues to increase, the complexity of balancing bleeding risks and thrombotic management has become increasingly critical in people with hemophilia with or at a high risk of thrombosis. Advances in hemophilia therapies such as extended half-life coagulation factors, non-factor therapies, rebalancing agents, and gene therapy have expanded treatment options for a variety of people with hemophilia. The thrombotic risk of people with hemophilia in general are relatively low as compared to those without hemophilia. However, antithrombotic therapy for prevention and treatment for thrombosis should still be considered in some situations, even in hemophilia. This clinical focus highlights the use of antithrombotic therapy in the management of thrombosis in people with hemophilia. A multidisciplinary, personalized approach is essential for optimizing the safety and efficacy of antithrombotic therapy in people with hemophilia with or at a high risk of thrombosis. High performance computer based multidimensional data analysis may help in establishing the personalized antithrombotic therapy in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AThrombosisFibrinolytic AgentsBlood CoagulationHumansHemorrhagePrecision MedicineRisk FactorsTreatment Outcome

Substanzen

Fibrinolytic Agents

Autor:innen und Institutionen

  • Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
  • Department of Hematology and Oncology, Kansai Medical University Hospital, Osaka, Japan.
  • Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan.
  • Department of Medicine (Cardiology), Tokai University School of Medicine, Kanagawa, Japan.

ORCID-Profile: Azusa Nagao, Shinichi Goto, Shinya Goto

Zitieren

APA

Nagao, A., Goto, S., & Goto, S. (2025). Antithrombotic Therapy in People with Hemophilia—A Narrative Review. Thrombosis and Haemostasis, 125(11), 1060-1068. https://doi.org/10.1055/a-2548-4192

Vancouver

Nagao A, Goto S, Goto S. Antithrombotic Therapy in People with Hemophilia—A Narrative Review. Thrombosis and Haemostasis. 2025;125(11):1060-1068. doi:10.1055/a-2548-4192

BibTeX
@article{Nagao2025,
  author = {Nagao, Azusa and Goto, Shinichi and Goto, Shinya},
  title = {Antithrombotic Therapy in People with Hemophilia—A Narrative Review},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {11},
  pages = {1060--1068},
  doi = {10.1055/a-2548-4192}
}
Kostenlos starten →